I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Roche and Genentech at

ECTRIMS 2024

September 17 - September 20

Copenhagen, Denmark

ectrims.eu

Medical Materials

Agenda

Coming soon

06:00 AM

Duration 72hrs Copenhagen, Denmark

Smartphone-based assessment of gait with Floodlight in multiple sclerosis shows sensitivity to change over a follow-up period of 3 years

João Rodrigues, Guy Bogaarts, Andrea Festanti, Cedric Simillion, Stanislas Hubeaux, Vittorio P Illiano, Letizia Leocani, Marisa P McGinley, Maria P Sormani, Giancarlo Comi, Agne Kazlauskaite, Licinio Craveiro, Mike D Rinderknecht, Mattia Zanon, Helmut Butzkueven

Neuroscience | Multiple Sclerosis

01:00 PM

Duration 10mins Room A3

Evaluation of CHIT1 and SERPINA3 as candidate cerebrospinal fluid biomarkers of progressive biology in multiple sclerosis

Amit Bar-Or, Jeffrey M. Gelfand, Chinaza Agbim, H. Christian von Buedingen, Briana Cameron, Ann E. Herman, Xiaoming Jia, Akshaya Ramesh, Ryan C. Winger, Jenny Jiang, Christopher Harp, Anne H. Cross

Neuroscience | Multiple Sclerosis

Duration 10mins Room A3

Long-Term Effect of Ocrelizumab on Brain Volume and Lesion Activity Outcomes in Patients with Relapsing Multiple Sclerosis: Analysis of 10-Year Data from the OPERA Trials

Granziera C, Kolind S, Traboulsee A, Hauser S, Bonati U, Wang Q, von Buren G, Clayton D, Craveiro L, Arnold DL

Neuroscience | Multiple Sclerosis

Duration 10mins Room A3

Reduced cerebrospinal fluid biomarkers (neurofilament light chain, B cells, T cells) and improved clinical/imaging assessments of disease activity are sustained after 5 years of ocrelizumab treatment: long-term extension results from OBOE

Anne Cross, Jeffrey Gelfand, H. Christian von Buedingen, David Clayton, Briana Cameron, Ann E. Herman, Xiaoming Jia, Chris Harp, Ryan Winger, Amit Bar-Or

Neuroscience | Multiple Sclerosis

01:04 PM

Duration 7mins Room A1

Ocrelizumab Dose Selection for Treatment of Pediatric Relapsing-Remitting Multiple Sclerosis: Pharmacokinetic, Safety, and Efficacy Results From OPERETTA 1 (NCT04075266)

Kotulska K, Valeriani M, Mar S, Steinborn B, Schreiner T, Waubant E, Filippi M, Mazurkiewicz-Beldzinska M, Manilus C, Campos N, Peill E, Kletzl H, Lin CJ, El-Azzouzi B, Shen YA, Banwell B

Neuroscience | Multiple Sclerosis

02:15 PM

Duration 2hrs Copenhagen, Denmark

B cell levels and placental transfer in infants potentially exposed to ocrelizumab during pregnancy: Analysis of the Phase IV MINORE study

Hellwig K, Bove R, Dobson R, Vukusic S, Oreja-Guevara C, McElrath T, Pietrasanta C, Maillart E, Jacobs D, Pasquarelli N, Lin CJ, Craviero L, Zecevic D, Kazlauskaite A, Raposo C

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Pregnancy and infant outcomes in women with multiple sclerosis receiving ocrelizumab: Analysis of approximately 4,000 pregnancies to date

Dobson R, Vukusic S, Bove R, Hellwig, K, Krysko KM, Pietrasanta C, McElrath T, Craveiro L, Ferreira G, Goncalves Pereira Alves D, Zecevic D, Lin CJ, Pasquarelli N, Oreja-Guevara C

Neuroscience | Multiple Sclerosis

Duration 3hrs Copenhagen, Denmark

Safety of ocrelizumab in multiple sclerosis: Up to 11 years of updated analysis in patients with relapsing and progressive multiple sclerosis

Hauser SL, Kappos L, Montalban X, Chognot C, Pasquarelli N, Punia V, Incera E, El Azzouzi B, Wolinsky JS

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Clinical outcomes among persons with relapsing multiple sclerosis initiating first-line treatment with ocrelizumab: Insights from real-world studies MSBase OCR-R substudy, MuSicalE and CONFIDENCE

Butzkueven H, Hobart J, Bluemich S, Buttmann M, Camerlingo S, Craveiro L, Cutter G, Farr P, Meuth S, Muros-Le Rouzic E, Rovira A, Spelman T, Trojano M, van der Walt A, Weber M, Ziemssen T

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Multiple Sclerosis Progression Prediction Based on Machine Learning

Ghazaleh N, Baker M, Overell J

Neuroscience | Multiple Sclerosis

12:01 AM

Duration 24hrs Copenhagen, Denmark

Anti-IL-6 receptor antibody attenuates myelitis severity of AQP4 peptide immunized mice

Katsura Y, Miyake S, Baba M, Tomizawa-Shinohara H, Matsumoto Y, Serizawa K

Neuroscience | Multiple Sclerosis

08:10 AM

Duration 10mins Room A2

B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: Primary results of the prospective, multicentre, open-label, phase IV study SOPRANINO

Bove R, Oreja-Guevara C, Hellwig K, Vukusic S, Shah A, Graham E, McElrath T, Pietrasanta C, Kletzl H, Kazlauskaite A, Zecevic D, Raposo C, Craviero L, Lin C-J, Pasquarelli N, Dobson R

Neuroscience | Multiple Sclerosis

02:45 PM

Duration 2hrs Copenhagen, Denmark

Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: results from the FENopta trial open-label extension

Amit Bar-Or, Jiwon Oh, Michal Dufek, Hrvoje Budincevic, Mario Habek, Maresa Caunt, Piia Thomas, Malgorzata Sierzega, David Clayton, Ying-Fang Chen, John N. Ratchford, Alexandra Goodyear, Jelena Drulovic

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Exposure-response analysis of fenebrutinib in patients with relapsing multiple sclerosis

Denison Kuruvilla, Michelle Deng, Anita Moein, Malgorzata Sierzega, Qi Qi, Alexandra Goodyear, Lin Pan, Nastya Kassir, Maria-Pia Sormani, Gavin Giovannoni, Yan Xu

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Elucidating the potential of Fenebrutinib, a noncovalent and reversible Bruton's tyrosine kinase inhibitor, to modulate microglial inflammation in human brain cell systems

Julie Langlois, Simona Lange, William Macnair, Martin Ebeling, Roland Schmucki, Jonathan DeGeer, Tania Sudharshan, Yun-An Shen, Christopher Harp, Ludovic Collin, James Keaney

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Early treatment with ocrelizumab: a multicentre, real-world observational study

Enrique Alvarez, Robert T. Naismith, Le H. Hua, Nicole G. Bonine, Ryan C. Winger, Hela Romdhani, Annie Guérin, Mohira Lévesque-Leroux, Gayatri Marathe, Daniel Ontaneda

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Two-year analysis of efficacy and safety data from Black and Hispanic people with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial

Nancy L Monson, Gregory F. Wu, Fernando Cuascut, Lilyana Amezcua, Williams, Mitzi, Bertnitsas, Evanthia, Anthony T Reder, Hooker, Juzar, Dilraj Sokhi, Nourbaksh, Bardia, Ahmed Obeidat, Harp, Christopher, Pei, Jinglan, Abioye, Ibraheem, Timothy Vartanian

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Smartphone-based assessment of gait with Floodlight in multiple sclerosis shows high operational robustness and analytical validity against reference tool

Natan Napiórkowski, Lorenza Angelini, Dimitar Stanev, Rafal Klimas, Marta Plonka, Gabriela Gonzolez Chan, Lisa Bunn, Paul S Glazier, Jonathan Marsden, Jeremy Hobart, Licinio Craveiro, Mattia Zanon, Mike D Rinderknecht

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Smartphone-based assessment of gait with Floodlight shows agreement with clinical measures of disability and gait impairment in multiple sclerosis

Andrea Festanti, Dimitar Stanev, Lorenza Angelini, Marta Plonka, Natan Napiórkowski, Rafal Klimas, Stanislas Hubeaux, Richard Hosking, Letizia Leocani, Giancarlo Comi, Agne Kazlauskaite, Helmut Butzkueven, Jeremy Hobart, Licinio Craveiro, Jonathan Marsden, Mattia Zanon, Mike D Rinderknecht

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

1H-MR spectroscopy metabolite concentration as a marker of brain injury in progressive multiple sclerosis

Marco Ganzetti, Stanislas Hubeaux, Daria Rukina, Qing Wang, Anton Belousov, Agne Kazlauskaite, Sridar Narayanan, Roland G. Henry, Declan T. Chard, Giancarlo Comi, Licinio Craveiro, Douglas Arnold

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Ocrelizumab treatment and risk for composite disability progression in non-Hispanic Black and Hispanic or Latino individuals by self-identity and genetic ancestry with relapsing multiple sclerosis: findings from the OPERA I and II trials

Lilyana Amezcua, Devi Sai Sri Kavya Boorgu, Jake Oxendine, Ibraheem Abioye, Tushar Bhangale, Christopher Harp, Chien-Ju Lin, Nicolas Strauli, Akshaya Ramesh, Bruce Cree, Mitzi Williams, Xiaoming Jia

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Circulating B-cell and serum neurofilament light chain levels associated with progressive disease outcomes in Phase III trials of ocrelizumab in people with relapsing or progressive multiple sclerosis

Stephen L. Hauser, Nicolas Strauli, Anastasiia Raievska, Christopher Harp, Harold Koendgen, Heidemarie Kletzl, Ulrike Bonati, Xiaoming Jia, Ann E. Herman, Ludwig Kappos, Amit Bar-Or

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Disease activity before, during and after pregnancy in women with MS receiving ocrelizumab: an integrated analysis from 13 interventional clinical trials

Vukusic S, Perrin Ross A, Marfia G, Bove R, Dobson R, Hellwig K, Lin C-J, Pasquarelli N, Oreja-Guevara C

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Two-year Results of Patient-Reported Outcomes in Patients with Multiple Sclerosis Treated with Ocrelizumab in a Large Real-World Setting: MuSicalE Interim Analysis

Trojano M, Pesch V can, Alroughani R, Rovira A, Cutter G, Dzhenkova D, Hagenbuch N, Camerlingo S, Craveiro L, Hobart J

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Real-World persistence, adherence and treatment satisfaction in patients with relapsing-remitting multiple sclerosis treated with Ocrelizumab

Trojano M, van Pesch V, Alroughani R, Rovira A, Cutter G, Dzhenkova D, Hagenbuch N, Camerlingo S, Craveiro L, Hobart J

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Ocrelizumab Subcutaneous Injection in Patients with Multiple Sclerosis: Further Characterisation of the Benefit - Risk Profile from the OCARINA Clinical Development Programme

Newsome SD, Krzystanek E, Selmaj K, Goldstick L, Bermel R, Figueiredo C, Townsend B, Augustin A, Zecevic D, Giacobino C, Bortolami O, Shen YA, Schneble H-M, Centonze D

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

Hauser SL, Giovannoni G, Filippi M, Weber MS, Montalban X, Nicholas JA, Schneble HM, Wang Q, Kappos L

Neuroscience | Multiple Sclerosis

Duration 2hrs Copenhagen, Denmark

Effectiveness and safety of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in Neuromyelitis Optica Spectrum Disorders: A six-month interim analysis of a multicenter medical chart review

Fujihara K, Isobe N, Miyamoto K, Niino M, Nakahara J, Hattori S, Yamamoto M, Kawachi I, Matsui N, Nohara C, Kokubun N, Chihara N, Misu T, Okada K, Yamashita K, Nagatsuka T, Adachi H, Nakashima I

Neuroscience | Multiple Sclerosis